256 related articles for article (PubMed ID: 14640387)
1. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors.
Martínez E; Domingo P; Ribera E; Milinkovic A; Arroyo JA; Conget I; Pérez-Cuevas JB; Casamitjana R; de Lazzari E; Bianchi L; Montserrat E; Roca M; Burgos R; Arnaiz JA; Gatell JM
Antivir Ther; 2003 Oct; 8(5):403-10. PubMed ID: 14640387
[TBL] [Abstract][Full Text] [Related]
2. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy.
Kohli R; Shevitz A; Gorbach S; Wanke C
HIV Med; 2007 Oct; 8(7):420-6. PubMed ID: 17760733
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
[TBL] [Abstract][Full Text] [Related]
5. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
[TBL] [Abstract][Full Text] [Related]
7. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.
Temple ME; Koranyi KI; Nahata MC
Ann Pharmacother; 2003 Sep; 37(9):1214-8. PubMed ID: 12921501
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
[TBL] [Abstract][Full Text] [Related]
9. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
[TBL] [Abstract][Full Text] [Related]
10. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
11. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
13. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
[TBL] [Abstract][Full Text] [Related]
15. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
[TBL] [Abstract][Full Text] [Related]
16. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F;
Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053
[TBL] [Abstract][Full Text] [Related]
17. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
Slama L; Lanoy E; Valantin MA; Bastard JP; Chermak A; Boutekatjirt A; William-Faltaos D; Billaud E; Molina JM; Capeau J; Costagliola D; Rozenbaum W
Antivir Ther; 2008; 13(1):67-76. PubMed ID: 18389900
[TBL] [Abstract][Full Text] [Related]
18. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
[TBL] [Abstract][Full Text] [Related]
19. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
Andersen O; Haugaard SB; Flyvbjerg A; Andersen UB; Ørskov H; Madsbad S; Nielsen JO; Iversen J
Eur J Clin Invest; 2004 Aug; 34(8):561-8. PubMed ID: 15305891
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study.
Rabing Christensen E; Stegger M; Jensen-Fangel S; Laursen AL; Ostergaard L
Clin Infect Dis; 2004 Nov; 39(9):1371-9. PubMed ID: 15494915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]